Hologic (Nasdaq:HOLX) was an interesting undervalued health care play when the company was waiting on approval for its tomosynthesis product (a better type of breast imaging technology). With approval in hand, though, now the concerns move to customer adoption and low patient volumes throughout the testing business. Though still an attractive and high-quality franchise, the company is going to need to deliver more growth to get the Street excited about the name.

TUTORIAL: Economic Indicators To Know

A Fiscal Q2 That's Solid, but Not Spectacular
Hologic delivered a modest outperformance for the fiscal second quarter. Revenue rose about 5%, fueled by nearly 9% growth in the breast health business, as the company saw good pricing and some early adoption of the tomosynthesis product. Diagnostics was still weak (down more than 1%), though, as patient visit volume has not rebounded yet. Gyn/surgical and skeletal were both up above the company average, but these are smaller units.

The company delivered less good news on the margins. Gross margin slid a bit on product mix issues, and adjusted operating income fell 3%. All in all, though, the operating performance is not too troubling. The company's service costs were flat and administrative costs grew less than revenue. R&D and sales costs were the main drivers of the decline in operating profit, but neither are long-term worries - investors should expect higher sales to support the tomosynthesis rollout and higher R&D is the cost of staying in the game in med-tech.

Big Iron Getting Better
Hologic certainly has a lead on General Electric (NYSE:GE) and Siemens (NYSE:SI) in 3D breast tomosynthesis, but that does not make it an easy sell. These systems cost multiple hundreds of thousands of dollars and though the hospital capital budget environment is getting better, that is still a big outlay. Investors are probably right to think of this as a "when, not if" market, but the longer it takes for capital spending to rebound, the more of a competitive threat other companies will be.

Volume? Not So Much
When it comes to the diagnostics side, Hologic has issues similar to Qiagen (Nasdaq:QGEN), Gen-Probe (Nasdaq:GRPO), Abbott (NYSE:ABT) and Becton Dickinson (NYSE:BDX) - patient visit counts are weak and there is an arms race in the lab. Hologic's ThinPrep is good technology, but BDX will not just concede the market. Likewise, Hologic's Invader platform is solid, but Gen-Probe's Panther and BDX's MAX products are legitimate threats in their own right.

The Bottom Line
Right now, Hologic looks like it is basically fairly valued on the basis of mid-single digit revenue growth and some modest improvements in free cash flow margin. If the company can drive better tomosynthesis adoption and/or patient visits rebound strongly, there could be some upside in those numbers.

Longer term, this is a great focused business and it does not seem too outlandish to think that it will be an M&A target. The lack of growth in the business is probably an impediment today, but it could be an appealing option to whichever diagnostics companies find that they cannot compete effectively in the next-gen molecular diagnostics market.

In the meantime, this is another one of those well-run med-techs that is a decent hold but not so compelling for new money. (For related reading, also take a look at Investing In The Healthcare Sector.)

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Stock Analysis

    Net Neutrality: Pros and Cons

    The fight over net neutrality has become an amazing spectacle. But at its core, it's yet another skirmish in cable television's war to remain relevant.
  2. Personal Finance

    Protect Your Home From Medicaid Liens

    Plan ahead for long-term care needs to protect your home and your estate.
  3. Personal Finance

    A Day in the Life of an Equity Research Analyst

    What does an equity research analyst do on an everyday basis?
  4. Mutual Funds & ETFs

    ETF Analysis: PowerShares S&P 500 Downside Hedged

    Find out about the PowerShares S&P 500 Downside Hedged ETF, and learn detailed information about characteristics, suitability and recommendations of it.
  5. Mutual Funds & ETFs

    ETF Analysis: ProShares Large Cap Core Plus

    Learn information about the ProShares Large Cap Core Plus ETF, and explore detailed analysis of its characteristics, suitability and recommendations.
  6. Mutual Funds & ETFs

    ETF Analysis: iShares Core Growth Allocation

    Find out about the iShares Core Growth Allocation Fund, and learn detailed information about its characteristics, suitability and recommendations.
  7. Mutual Funds & ETFs

    ETF Analysis: iShares MSCI USA Minimum Volatility

    Learn about the iShares MSCI USA Minimum Volatility exchange-traded fund, which invests in low-volatility equities traded on the U.S. stock market.
  8. Stock Analysis

    Should You Follow Millionaires into This Sector?

    Millionaire investors—and those who follow them—should take another look at the current economic situation before making any more investment decisions.
  9. Professionals

    What to do During a Market Correction

    The market has corrected...now what? Here's what you should consider rather than panicking.
  10. Mutual Funds & ETFs

    ETF Analysis: Vanguard Mid-Cap Value

    Take an in-depth look at the Vanguard Mid-Cap Value ETF, one of the largest and most popular mid-cap funds in the U.S. equity space.
RELATED TERMS
  1. Equity

    The value of an asset less the value of all liabilities on that ...
  2. Hard-To-Sell Asset

    An asset that is extremely difficult to dispose of either due ...
  3. Sucker Yield

    When an investor has essentially risked all of his capital for ...
  4. PT (Perseroan Terbatas)

    An acronym for Perseroan Terbatas, which is Limited Liability ...
  5. Ltd. (Limited)

    An abbreviation of "limited," Ltd. is a suffix that ...
  6. BHD (Berhad)

    The suffix Bhd. is an abbreviation of a Malay word "berhad," ...
RELATED FAQS
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>

You May Also Like

COMPANIES IN THIS ARTICLE
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!